JP2015528801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528801A5 JP2015528801A5 JP2015521817A JP2015521817A JP2015528801A5 JP 2015528801 A5 JP2015528801 A5 JP 2015528801A5 JP 2015521817 A JP2015521817 A JP 2015521817A JP 2015521817 A JP2015521817 A JP 2015521817A JP 2015528801 A5 JP2015528801 A5 JP 2015528801A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- composition
- disorder
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 239000001301 oxygen Chemical group 0.000 claims description 23
- 208000035475 disorder Diseases 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
- 229910052717 sulfur Chemical group 0.000 claims description 20
- 239000011593 sulfur Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims description 14
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 230000001684 chronic effect Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 230000001363 autoimmune Effects 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 201000002481 Myositis Diseases 0.000 claims description 6
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 4
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000005141 Otitis Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 208000019258 ear infection Diseases 0.000 claims description 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 230000009826 neoplastic cell growth Effects 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000001297 phlebitis Diseases 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims description 3
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims description 3
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 206010001889 Alveolitis Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 241000272517 Anseriformes Species 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 208000023611 Burkitt leukaemia Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 206010048832 Colon adenoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010057254 Connective tissue inflammation Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 241001317099 Dystaxia Species 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000004145 Endometritis Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 206010014950 Eosinophilia Diseases 0.000 claims description 2
- 206010015218 Erythema multiforme Diseases 0.000 claims description 2
- 206010016228 Fasciitis Diseases 0.000 claims description 2
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 2
- 206010016717 Fistula Diseases 0.000 claims description 2
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
- 206010062639 Herpes dermatitis Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 201000008197 Laryngitis Diseases 0.000 claims description 2
- 206010024238 Leptospirosis Diseases 0.000 claims description 2
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims description 2
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims description 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 208000003926 Myelitis Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010029350 Neurotoxicity Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010034038 Parotitis Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 206010035742 Pneumonitis Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 206010036105 Polyneuropathy Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 208000028561 Primary cutaneous T-cell lymphoma Diseases 0.000 claims description 2
- 206010036774 Proctitis Diseases 0.000 claims description 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims description 2
- 206010037549 Purpura Diseases 0.000 claims description 2
- 241001672981 Purpura Species 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 208000004760 Tenosynovitis Diseases 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 2
- 206010046914 Vaginal infection Diseases 0.000 claims description 2
- 201000008100 Vaginitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 208000037883 airway inflammation Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000001925 catabolic effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 206010008323 cervicitis Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 208000003167 cholangitis Diseases 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 208000027710 cyclic fever Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 230000001066 destructive effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 208000007784 diverticulitis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000002169 ectodermal dysplasia Diseases 0.000 claims description 2
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 208000010227 enterocolitis Diseases 0.000 claims description 2
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims description 2
- 210000000918 epididymis Anatomy 0.000 claims description 2
- 201000010063 epididymitis Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000002449 erythroblastic effect Effects 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 208000030941 fetal growth restriction Diseases 0.000 claims description 2
- 230000003890 fistula Effects 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 210000004276 hyalin Anatomy 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000003849 large cell carcinoma Diseases 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 231100000228 neurotoxicity Toxicity 0.000 claims description 2
- 230000007135 neurotoxicity Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 206010057056 paraneoplastic pemphigus Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 208000008423 pleurisy Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 230000007824 polyneuropathy Effects 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 230000001185 psoriatic effect Effects 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 238000007634 remodeling Methods 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims description 2
- 230000003393 splenic effect Effects 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 208000003265 stomatitis Diseases 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 210000000106 sweat gland Anatomy 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 206010044008 tonsillitis Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 208000002003 vulvitis Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 15
- 0 *C(CC1)Cc2c1[s]c1c2c(I)cc(*)n1 Chemical compound *C(CC1)Cc2c1[s]c1c2c(I)cc(*)n1 0.000 description 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670380P | 2012-07-11 | 2012-07-11 | |
| US61/670,380 | 2012-07-11 | ||
| US201261682622P | 2012-08-13 | 2012-08-13 | |
| US61/682,622 | 2012-08-13 | ||
| PCT/US2013/050113 WO2014011906A2 (en) | 2012-07-11 | 2013-07-11 | Irak inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015528801A JP2015528801A (ja) | 2015-10-01 |
| JP2015528801A5 true JP2015528801A5 (enExample) | 2016-09-08 |
Family
ID=49914493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521817A Pending JP2015528801A (ja) | 2012-07-11 | 2013-07-11 | Ｉｒａｋ阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9067948B2 (enExample) |
| EP (1) | EP2872518A4 (enExample) |
| JP (1) | JP2015528801A (enExample) |
| CN (1) | CN104902959A (enExample) |
| AU (1) | AU2013290080A1 (enExample) |
| BR (1) | BR112015000561A2 (enExample) |
| CA (1) | CA2878040A1 (enExample) |
| HK (1) | HK1210732A1 (enExample) |
| IN (1) | IN2015DN00127A (enExample) |
| WO (1) | WO2014011906A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012097013A1 (en) | 2011-01-10 | 2012-07-19 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP6126131B2 (ja) | 2012-01-10 | 2017-05-10 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| WO2014011906A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CA2890911A1 (en) | 2013-01-10 | 2014-07-17 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| CN106232122A (zh) | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| AR102849A1 (es) * | 2015-03-09 | 2017-03-29 | Astellas Pharma Inc | Compuesto de piridina bicíclica |
| MX382156B (es) | 2015-08-28 | 2025-03-13 | Chdi Foundation Inc | Sondas para formar imagenes de proteina de huntingtina. |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| ES2978674T3 (es) * | 2018-06-25 | 2024-09-17 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuesto de isotiazolo[5,4-d]pirimidina como inhibidor de IRAK4 |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| US12171768B2 (en) | 2021-02-15 | 2024-12-24 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1346358A (zh) | 1999-03-30 | 2002-04-24 | 日本曹达株式会社 | 噻吩并嘧啶化合物及其盐和制备方法 |
| MXPA03009925A (es) | 2001-04-30 | 2004-06-30 | Bayer Pharmaceuticals Corp | Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas. |
| WO2003057149A2 (en) | 2001-12-28 | 2003-07-17 | Bayer Corporation | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
| US20030225098A1 (en) | 2002-03-21 | 2003-12-04 | Hirst Gavin C. | Kinase inhibitors |
| WO2004041285A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
| US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| PE20060526A1 (es) * | 2004-06-15 | 2006-07-13 | Schering Corp | Compuestos triciclicos como antagonistas de mglur1 |
| EP1619196A1 (de) * | 2004-07-23 | 2006-01-25 | Curacyte Discovery GmbH | Substituierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und Pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur Verwendung als Inhibitoren der PDA-4 und/oder TNF-alpha Freisetzung |
| DE502005008916D1 (de) | 2004-07-23 | 2010-03-11 | Medicines Co Leipzig Gmbh | Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung |
| WO2006081072A1 (en) * | 2005-01-24 | 2006-08-03 | Abbott Laboratories | Antagonists of the mglu receptor and uses thereof |
| CA2655799A1 (en) * | 2005-06-22 | 2006-12-28 | Develogen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
| US7687501B2 (en) * | 2005-08-19 | 2010-03-30 | Schering Corporation | Pyridothienopyridazinone derivatives as mGluR1 antagonists |
| US7767815B2 (en) * | 2005-08-19 | 2010-08-03 | Schering Corporation | Fused tricyclic mGluR1 antagonists as therapeutic agents |
| EP2132211A4 (en) | 2006-11-09 | 2011-12-07 | Ardea Biosciences Inc | 4-CYANPHENYLAMINO-SUBSTITUTED BICYCLIC AND HETEROCYCLIC COMPOUNDS AS AN HIV HEMMER |
| US20100227853A1 (en) | 2008-04-18 | 2010-09-09 | Trustees Of Boston College | Inhibitors of cyclic amp phosphodiesterases |
| CN102186479A (zh) | 2008-09-10 | 2011-09-14 | 凯利普西斯公司 | 用于治疗疾病的组胺受体的氨基嘧啶抑制剂 |
| CN102984941B (zh) | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| CN110003219A (zh) | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| EP2595993B1 (en) | 2010-07-23 | 2018-04-18 | President and Fellows of Harvard College | Tricyclic proteasome activity enhancing compounds |
| WO2012097013A1 (en) | 2011-01-10 | 2012-07-19 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2013078126A1 (en) | 2011-11-23 | 2013-05-30 | Cancer Research Technology Limited | Thienopyrimidine inhibitors of atypical protein kinase c |
| JP6126131B2 (ja) | 2012-01-10 | 2017-05-10 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| WO2014011911A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2014011906A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
-
2013
- 2013-07-11 WO PCT/US2013/050113 patent/WO2014011906A2/en not_active Ceased
- 2013-07-11 HK HK15111414.8A patent/HK1210732A1/xx unknown
- 2013-07-11 EP EP13817012.1A patent/EP2872518A4/en not_active Withdrawn
- 2013-07-11 CN CN201380036906.2A patent/CN104902959A/zh active Pending
- 2013-07-11 JP JP2015521817A patent/JP2015528801A/ja active Pending
- 2013-07-11 IN IN127DEN2015 patent/IN2015DN00127A/en unknown
- 2013-07-11 BR BR112015000561A patent/BR112015000561A2/pt not_active IP Right Cessation
- 2013-07-11 CA CA2878040A patent/CA2878040A1/en not_active Abandoned
- 2013-07-11 AU AU2013290080A patent/AU2013290080A1/en not_active Abandoned
- 2013-07-11 US US13/939,816 patent/US9067948B2/en not_active Expired - Fee Related
-
2015
- 2015-06-17 US US14/741,916 patent/US20160002256A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528801A5 (enExample) | ||
| JP2016531870A5 (enExample) | ||
| JP2015503618A5 (enExample) | ||
| RU2016140870A (ru) | Ингибиторы irak и их применения | |
| RU2016110852A (ru) | Ингибиторы irak и их применения | |
| IL303987A (en) | IRAK joints and their uses | |
| JP2022538192A5 (enExample) | ||
| ES2975436T3 (es) | Enantiómeros (R) y (S) de n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4- il)oxazol-carboxamida como inhibidores de IRAK4 para el tratamiento del cáncer | |
| AU2019364336B2 (en) | TYK2 inhibitors and uses thereof | |
| JP2017505337A5 (enExample) | ||
| JP7474527B2 (ja) | インダゾール誘導体ならびにその調製方法および応用 | |
| JP2017502088A5 (enExample) | ||
| JP2022516401A5 (enExample) | ||
| AU2016283105C1 (en) | 4,6-pyrimidinylene derivatives and uses thereof | |
| CN115448923B (zh) | 嘧啶并环化合物及其制备方法和应用 | |
| JP2017518348A5 (enExample) | ||
| AU2021323304A1 (en) | Compound for targeting and degrading protein, and preparation method therefor and use thereof | |
| AU2020214351A1 (en) | Indolo heptamyl oxime analogue as PARP inhibitor | |
| US20130096136A1 (en) | Inhibitors of Protein Tyrosine Kinase Activity | |
| WO2019193540A1 (en) | Heteroaryl derivatives of formula (i) as atf4 inhibitors | |
| BR112020013164A2 (pt) | derivados da amino-fluorpiperidina como inibidor da quinase | |
| AU2021373162B2 (en) | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof | |
| US11753418B2 (en) | Compounds for the modulation of Myc activity | |
| US20230066011A1 (en) | Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient | |
| BR112014017735B1 (pt) | Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto |